CONTACT US

Publications

egnite Introduces Customer Access to Its National Cardiovascular Registry and Launches 2026 Call for Science Investigator-Initiated Study Program

February 24, 2026

egnite, Inc., a leading digital health company specializing in cardiovascular care, today announced the addition of two distinguished physicians, Vinod H. Thourani, MD and Nicholas Amoroso, MD to its Medical Advisory Board. Their wealth of expertise in cardiovascular care and dedication to innovation will significantly contribute to egnite’s mission to

Read More »

Cath Lab Capacity is Up—But Structural Heart Procedures Are Being Outpaced by Other Interventions

September 30, 2025

Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient

Read More »

egnite Launches CardioCare Research Suite to Accelerate Patient Identification for Leading Cardiovascular Clinical Trials

July 1, 2025

ALISO VIEJO, Calif. – July 1, 2025 – egnite, Inc., a leading digital health company advancing cardiovascular innovation, today announced the launch of its new CardioCare Research Suite, a significant expansion of its flagship platform that enables hospitals to automatically identify patients eligible for clinical trials across participating health systems.

Read More »

SGLT2i + GLP-1 RA: A Dynamic Duo in HFpEF?

March 13, 2025

Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient

Read More »